Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15050375 | 1.00 | HTR7 (0.41) | HTR7LMNAAOC3MEN1KMT2A | |
| SCHEMBL15050374 | 1.00 | HTR7 (0.41) | HTR7LMNAAOC3MEN1KMT2A | |
| SCHEMBL15050377 | 1.00 | HTR7 (0.41) | HTR7LMNAAOC3MEN1KMT2A | |
| SCHEMBL15051115 | 1.00 | HTR7 (0.41) | HTR7LMNAAOC3MEN1KMT2A | |
| SCHEMBL9909063 | 0.84 | HTR7 (0.40) | HTR7LMNAAOC3MEN1KMT2A | |
| SCHEMBL18503058 | 0.82 | AOC3 (0.52) | HTR7AOC3MEN1KMT2AALDH1A1 | |
| SCHEMBL15352372 | 0.81 | HTR7 (0.41) | HTR7LMNAAOC3MEN1KMT2A | |
| SCHEMBL15050822 | 0.80 | AOC3 (0.44) | AOC3MEN1KMT2AALDH1A1CYP19A1 | |
| SCHEMBL15050516 | 0.80 | AOC3 (0.44) | AOC3MEN1KMT2AALDH1A1CYP19A1 | |
| SCHEMBL15050517 | 0.80 | AOC3 (0.44) | AOC3MEN1KMT2AALDH1A1CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2024-03-19 | — | — | US | disclosed |
| CN-111419830-B | Phenylalkylcarbamate compounds for use in the prevention or treatment of epilepsy and epileptic related syndromes | 比皮艾思药物研发有限公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-4204395-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING NEURODEGENERATIVE DISEASE | Bio-Pharm Solutions Co., Ltd. (KR) | 2023-07-05 | — | — | EP | disclosed |
| CN-115996905-A | Phenylalkyl carbamate compounds for use in preventing or treating neurodegenerative diseases | 生物药品解决方案有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| EP-2968211-B1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO PHARM SOLUTIONS CO LTD (KR) | 2021-05-12 | — | — | EP | disclosed |
| EP-2797881-B1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | BIO PHARM SOLUTIONS CO LTD (KR) | 2018-11-14 | — | — | EP | disclosed |
| US-9504668-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-11-29 | — | — | US | disclosed |
| US-9504668-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-11-29 | — | — | US | disclosed |
| US-9504668-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating epilepsy or epilepsy-related syndrome | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-11-29 | — | — | US | disclosed |
| US-9029589-B2 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-05-12 | — | — | US | disclosed |
| US-9029589-B2 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-05-12 | — | — | US | disclosed |
| EP-2797881-A1 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | Bio-Pharm Solutions Co., Ltd. (KR) | 2014-11-05 | — | — | EP | disclosed |
| WO-2014142519-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014142519-A1 | PHENYL ALKYL CARBAMATE COMPOUNDS FOR USE IN PREVENTING OR TREATING EPILEPSY OR EPILEPSY-RELATED SYNDROME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013100566-A1 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013100566-A1 | Phenyl alkyl carbamate derivative compound and pharmaceutical composition containing the same | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-07-04 | — | — | WO | disclosed |
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165509-A1 | PHENYL ALKYL CARBAMATE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | MYLK, PDE3A, TNNC1 | HTR7 1288/4885LMNA 1572/4885AOC3 3584/4885 |
| US-11931332-B2 | Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease | SNCA, MAPT, CHAT | HTR7 4050/4885LMNA 2457/4885AOC3 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.